Skip to content

Erbitux

Published: July 26, 2026Updated: July 26, 2026

Erbitux (cetuximab) is a targeted cancer therapy belonging to the class of drugs called monoclonal antibodies. It works by targeting the epidermal growth factor receptor (EGFR), which is overexpressed on certain cancer cells, helping to slow or stop cancer cell growth and spread.

Quick summary

Erbitux is a prescription monoclonal antibody used to treat certain colorectal and head and neck cancers by blocking cancer cell growth signals.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

RxNorm
355460
Generic
Erbitux
Class
brand-name
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Erbitux is indicated for the treatment of certain types of metastatic colorectal cancer and squamous cell carcinoma of the head and neck. It may be used alone or in combination with other cancer therapies depending on the specific diagnosis and treatment plan determined by an oncologist.

Erbitux is a targeted therapy that binds specifically to the epidermal growth factor receptor (EGFR) on the surface of cancer cells. By blocking EGFR, it inhibits the signals that promote cancer cell growth, division, and survival, helping to control tumor progression.

Erbitux is administered by intravenous infusion in a clinical setting. Common side effects may include skin reactions, fatigue, nausea, and electrolyte imbalances. Patients should inform their healthcare provider of any allergies or infusion reactions. Regular monitoring and dermatological assessments may be needed during treatment. This medication should only be used under the supervision of an oncologist.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy